These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

597 related items for PubMed ID: 27324471

  • 1. Biomarkers and targeted new therapies for IgA nephropathy.
    Coppo R.
    Pediatr Nephrol; 2017 May; 32(5):725-731. PubMed ID: 27324471
    [Abstract] [Full Text] [Related]

  • 2. Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?
    Suzuki H, Allegri L, Suzuki Y, Hall S, Moldoveanu Z, Wyatt RJ, Novak J, Julian BA.
    Dis Markers; 2016 May; 2016():7806438. PubMed ID: 27647947
    [Abstract] [Full Text] [Related]

  • 3. Paradigm shift in activity assessment of IgA nephropathy - optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting.
    Suzuki Y, Suzuki H, Yasutake J, Tomino Y.
    Expert Opin Biol Ther; 2015 Apr; 15(4):583-93. PubMed ID: 25604055
    [Abstract] [Full Text] [Related]

  • 4. Mechanism of Yiqi Yangying Heluo Formula in the Treatment of IgA Nephropathy by Affecting Gd-IgA1 Based on BAFF Molecular Level and T Lymphocyte Immunity.
    Liang Y, Zeng Q, Wang XH, Yan L, Yu RH.
    Biomed Res Int; 2023 Apr; 2023():5124034. PubMed ID: 36660452
    [Abstract] [Full Text] [Related]

  • 5. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis.
    Suzuki H.
    Clin Exp Nephrol; 2019 Jan; 23(1):26-31. PubMed ID: 29740706
    [Abstract] [Full Text] [Related]

  • 6. Clinical Significance of Serum Galactose-Deficient IgA1 Level in Children with IgA Nephropathy.
    Irabu H, Shimizu M, Kaneko S, Inoue N, Mizuta M, Ohta K, Yachie A.
    J Immunol Res; 2020 Jan; 2020():4284379. PubMed ID: 32537466
    [Abstract] [Full Text] [Related]

  • 7. Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro.
    Lin L, Shen J, Wu X, You Y, Li S.
    J Vis Exp; 2023 Oct 13; (200):. PubMed ID: 37902367
    [Abstract] [Full Text] [Related]

  • 8. Potential diagnostic biomarkers for IgA nephropathy: a comparative study pre- and post-tonsillectomy.
    Xie YX, He LY, Chen X, Peng XF, Ye MY, Zhao YJ, Yan WZ, Liu C, Shao J, Peng YM.
    Int Urol Nephrol; 2016 Nov 13; 48(11):1855-1861. PubMed ID: 27465795
    [Abstract] [Full Text] [Related]

  • 9. Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study.
    Bagchi S, Lingaiah R, Mani K, Barwad A, Singh G, Balooni V, Bhowmik D, Agarwal SK.
    PLoS One; 2019 Nov 13; 14(3):e0214256. PubMed ID: 30917188
    [Abstract] [Full Text] [Related]

  • 10. Immunostaining of galactose-deficient IgA1 by KM55 is not specific for immunoglobulin A nephropathy.
    Zhao L, Peng L, Yang D, Chen S, Lan Z, Zhu X, Yuan S, Chen G, Liu Y, Liu H.
    Clin Immunol; 2020 Aug 13; 217():108483. PubMed ID: 32479989
    [Abstract] [Full Text] [Related]

  • 11. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.
    Wada Y, Matsumoto K, Suzuki T, Saito T, Kanazawa N, Tachibana S, Iseri K, Sugiyama M, Iyoda M, Shibata T.
    PLoS One; 2018 Aug 13; 13(11):e0206865. PubMed ID: 30388165
    [Abstract] [Full Text] [Related]

  • 12. Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy.
    Zhang K, Li Q, Zhang Y, Shang W, Wei L, Li H, Gao S, Yan T, Jia J, Liu Y, Lin S.
    Kidney Blood Press Res; 2019 Aug 13; 44(5):1196-1206. PubMed ID: 31574506
    [Abstract] [Full Text] [Related]

  • 13. A Novel Biomarker for Post-Transplant Recurrent IgA Nephropathy.
    Temurhan S, Akgul SU, Caliskan Y, Artan AS, Kekik C, Yazici H, Demir E, Caliskan B, Turkmen A, Oguz FS, Sever MS.
    Transplant Proc; 2017 Apr 13; 49(3):541-545. PubMed ID: 28340830
    [Abstract] [Full Text] [Related]

  • 14. Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors.
    Zachova K, Jemelkova J, Kosztyu P, Ohyama Y, Takahashi K, Zadrazil J, Orsag J, Matousovic K, Galuszkova D, Petejova N, Mestecky J, Raska M.
    J Am Soc Nephrol; 2022 May 13; 33(5):908-917. PubMed ID: 35115327
    [Abstract] [Full Text] [Related]

  • 15. Post-transplant immunoglobulin A deposition and nephropathy in allografts.
    Sofue T, Suzuki H, Ueda N, Kushida Y, Minamino T.
    Nephrology (Carlton); 2018 Jul 13; 23 Suppl 2():4-9. PubMed ID: 29968406
    [Abstract] [Full Text] [Related]

  • 16. Follicular Helper T Cells in Peyer's Patches and Galactose- Deficient Iga1 Contribute to Iga Nephropathy.
    Huang Y, Sun X, Nie G, Xu H, Zou M.
    Curr Mol Med; 2024 Jul 13; 24(8):1033-1044. PubMed ID: 37475555
    [Abstract] [Full Text] [Related]

  • 17. IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy.
    Lechner SM, Abbad L, Boedec E, Papista C, Le Stang MB, Moal C, Maillard J, Jamin A, Bex-Coudrat J, Wang Y, Li A, Martini PG, Monteiro RC, Berthelot L.
    J Am Soc Nephrol; 2016 Sep 13; 27(9):2622-9. PubMed ID: 26850635
    [Abstract] [Full Text] [Related]

  • 18. New Insights and Future Perspectives of APRIL in IgA Nephropathy.
    Muto M, Suzuki H, Suzuki Y.
    Int J Mol Sci; 2024 Sep 26; 25(19):. PubMed ID: 39408691
    [Abstract] [Full Text] [Related]

  • 19. Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression.
    Elíasdóttir S, Khramova A, Saeed A, Guron G, Boi R, Mölne J, Ebefors K, Nyström J.
    BMC Nephrol; 2023 Jun 07; 24(1):160. PubMed ID: 37286948
    [Abstract] [Full Text] [Related]

  • 20. LPS/TLR4 Pathway Regulates IgA1 Secretion to Induce IgA Nephropathy.
    He H, Shen M, Tang Y, Sun W, Xu X.
    Altern Ther Health Med; 2024 Jan 07; 30(1):419-425. PubMed ID: 37820669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.